The possibility that the opioid &receptor mediates antinociception in tests where heat is the noxious stimulus was investigated using highly selective ~-and 6-agonists and -antagonists. 
INTRODUCTION
The existence of the opioid b-receptor has generally been accepted based on findings in vitro 26. Its function in vivo, however, remains elusive in spite of a number of effects produced by administration of d-ligands. The interpretation of receptor involvement in these effects is difficult due to the interaction of most opioids at one or more of the multiple receptor subtypes suggested by evidence in vitro 26 and in vivo 12 "27, This problem has been difficult to resolve due to the lack of compounds with both a high degree of selectivity for any one opioid receptor, and biological halflives suitable for study in vivo 15 receptor-selective agonists serve as valuable probes with which specific functions can begin to be assigned to specific opioid receptors. Nevertheless, a high degree of selectivity alone, does not enable conclusions to be drawn as to receptor involvement in specific ef-hibition of nociception resulting from heat has been studied most extensively. Opioids have been shown to produce antinociception in heat models at both supraspinal and spinal sites ~'2'22'32'3&38. Based on the relationship between binding affinity, bioassay potency and analgesic potency, Audigier and colleagues 1 and Chaillet et al. 2 , have suggested that when heat is used as the noxious stimulus, all supraspinal opioid antinociception is the result of g-receptor activation. In contrast to this view, Galligan et al. H and Porreca et al. 32 have suggested a role for both the g-and the bopioid receptor in the supraspinal mediation of antinociception in tests employing heat. Supraspinal breceptor involvement was proposed on the grounds that g-agonists, such as DAGO and morphine, produce antinociception (hot-plate test) and inhibit small and gastrointestinal transit, while the highly bselective agonist, DPDPE, produces only antinociception without affecting gut propulsion after administration into the lateral cerebral ventricles of the rat 1~ or the mouse 32. Furthermore, based on the rank order of potencies, these investigators 32, and others 25, also suggest a role for the d-receptor in antinociception at spinal levels. These conclusions have remained controversial, however, especially at supraspinal sites, since the b-selective ligands remain less potent than/~-agonists in antinociceptive effects and the antinociceptive dose-response relationship for both g-and d-agonists is to the left of that for gut effects. Thus, it seems possible that highly d-selective agonists, such as DPDPE, might yet be acting at the g-receptor for antinociceptive effects in vivo. The present study was carried out in an attempt to further demonstrate a role for the d-opioid receptor in the production of supraspinal as well as spinal antinociception in a test utilizing heat as the noxious stimulus.
The approach was to use the most selective opioid agonists available, together with highly selective gand b-antagonists, in order to determine the importance of cerebral and spinal g-and d-receptors in the mouse warm-water tail-withdrawal test. The compounds studied included the d-selective DPDPE, the g-selective DAGO as well as morphine (reference g) as agonists; fl-funaltrexamine (fl-FNA) 33'41'42 was used as a non-surmountable g-antagonist, while ICI 174,864 (N,N-diallyI-Tyr-Aib-Aib-Phe-Leu-OH: Aib = a-amino-isobutyric acid) was studied as a competitive d-antagonist 5-7. We now report that DPDPE-, but not morphine-or DAGO-induced antinociception, is sensitive to antagonism by ICI 174,864; in contrast, fl-FNA antagonizes morphine and DAGO, but not DPDPE antinociception.
MATERIALS AND METHODS
DPDPE was synthesized as previously described 29 
Injection techniques
Supraspinal injections were made into the lateral ventricle. These intracerebroventricular (i.c.v.) injections were done by the modified method of Haley and McCormick 14 as previously described 32. The mice were lightly anesthetized with ether, an incision was made in the scalp and bregma was located. The injections were made 2 mm caudal and 2 mm lateral to bregma at a depth of 3 mm using a Hamilton (Reno, NV) microliter syringe with a 26-gauge needle. The intrathecal (i.th.) injections were made into the spinal subarachnoid space using a modified version of the method of Hylden and Wilcox 1~ as previously reported 31. Injections into the subarachnoid space were made in unanesthetized mice using a Hamilton microliter syringe fitted with a 30-gauge needle by direct lumbar puncture. All i.c.v, or i.th. injections were made in a vol. of 5/~1.
Antagonist administration
The i.c.v, fl-FNA pretreatment used was basically that described by Ward and Takemori 
Mouse tail-withdrawal test
Male, ICR mice (20-25 g) were used for all experiments. The animals were housed in groups of 5 in a temperature-controlled room with a 12 h light-dark cycle (lights on at 07.00 h). Food and water were continuously available. Warm (55 °C) water was employed as the nociceptive stimulus according to the method of Jannsen et al. 21 . Prior to agonist administration, the tail of each mouse was immersed in the water and the latency to a rapid flick recorded. Animals not flicking their tails within 5 s were not used in the study. This procedure was repeated 20 min after administration of all compounds by both routes, with the exception of i.th. DPDPE which was tested after 10 rain. These were the times of peak agonist effect as determined from time-response curves (data not shown). Mice not flicking their tails within 15 s were assigned a maximal score. Antinociception was expressed as: % antinociception = lt)0 x (test latencycontrol latency)/(15 -control latency).
Statistics"
Regression lines, As0 values (dose of agonist producing 50% antinociceptive effect) and 95% confidence limits (C.L.'s) were determined for each individual data point using the computer program of Tal . The effect of fl-FNA on antinociception at the spinal level was also studied, fl-FNA (0.1 or 1 #g) effectively antagonized both i.th. morphine and i.th. DPDPE antinociception. Further decreasing the i.th. pretreatment dose of fl-FNA (0.01, 0.005 #g) resuited in selective antagonism of i.th. morphine, but not i.th. DPDPE antinociception (Fig. 6 ).
DISCUSSION
Opioids have been found to function at both spinal 25'32'36'37'43 and supraspina122 sites in eliciting antinociception. A number of opioids have demonstrated varying degrees of selectivity for specific opioid receptors in vitro. Despite selectivity in vitro, it has been suggested that when heat is used as the noxious stimulus, all opioids which produce antinociception do so by activation of the H-receptor L2. Arguments against this view have been made based on the rank order of potency of the compounds 3:, and production of supraspinal antinociception without gastrointestinal effects 11'32. In spite of these approaches, b-receptor involvement in antinociception has remained controversial. Differential antagonism, however, has historically been accepted as the strongest pharmacological evidence for implication of multiple receptors. Using highly selective opioid agonists and antagonists, the present work now provides direct evidence of b-receptor involvement in the mediation of supraspinal and spinal antinociception in a test using heat as the noxious stimulus.
The b-selective antagonist, ICI 174,864 (ref. 5), effectively antagonized the i.c.v, antinociceptive effects of DPDPE but failed to antagonize i.c.v. DAGO or morphine. It should be noted that a previous study by Cowan et al. 6 found that ICI 174,864 produced postural abnormalities in rats, but not in mice. That study also showed that ICI 174,864 produced analgesia in the mouse writhing test at an i.c.v. (a proposed d-agonist) . This may be due to the;.fact that DADLE is much less d-selective than DPDPE 4't1'3°. While the precise site of action of flFlqA remains obscure, it is clear that this compound differentially antagonizes DAGO and morphine antinociception, but not that of DPDPE. A previous study by Dray and colleagues s, involving centrally mediated inhibition of rat urinary bladder motility, showed that fl-FNA lacked selectivity in antagonizing DAGO and DPDPE. That study, however, gave fl-FNA acutely prior to the administration of the agonists, rather than the 4-h pretreatment employed here, Thus, these studies are not directly comparable. Additionally, an earlier study by Frederickson et al. 1° studied fl-FNA in the mouse writhing test, concluding that this compound may either block at dreceptors, or that d-agonists may produce analgesia at sites which are coupled to B-receptors; the latter is not inconsistent with our interpretation and has been proposed based on other studies 39.
Although morphine is generally regarded as the prototype,u-agonist, and was used for that purpose in the present study, it is widely accepted that this agonist is not highly ,u-selective and has been shown to have agonist properties at the &receptor in vitro 4°. Our results reinforce this view. Pretreatment with the ,u-selective fl-FNA resulted in a 12-fold shift to the right for i.c.v, morphine, but a 958-fold shift to the right for i.c.v. DAGO. One explanation for this large difference in the magnitude of displacement may be due to the possible activity of morphine at dreceptors. To examine this possibility, i.c.v, morphine was tested in fl-FNA pretreated mice (10 ,ug i.c.v, at -4 h) in the absence and in the presence of ICI 174,864 (3,ug) . Fig. 1 shows that the d-antagonist ICI 174,864 had no effect, at this dose, on i.c.v, morphine antinociception in naive mice. In fl-FNA pretreated mice, however, ICI 174,864 was able to displace the i.c.v, morphine dose-response line to the right of fl-FNA displaced line. A complete i.c.v. ICI 174,864/morphine dose-response line in fl-FNA pretreated mice could not be achieved as the higher doses of morphine produced barrel rotation and seizures. Gmerek and Woods 13 have reported that fl-FNA-precipitated withdrawal in the morphine-dependent rhesus monkey could not be suppressed by cumulative doses of morphine while the same levels of deprivation-induced and naltrexone-precipitated withdrawal were reversible by cumulative doses of morphine. These findings indicate that the effects of fl-FNA at the g-receptor are insurmountable in vivo. With this in mind, it would seem that any antinociception produced by morphine in the fl-FNA pretreated mouse must be due to activation of receptors other than the ,u-receptor. As antinociception in the fl-FNA pretreated mouse is antagonized by ICI 174,864, the receptor through which morphine produces its effects would appear to be 6.
It should also be noted that other approaches have been studied in an effort to determine b-receptor involvement in supraspinal antinociception. Heyman et al. 17 estimated the naloxone pA: against morphine, DAGO and DPDPE at both supraspinal and spinal sites in the mouse tail-withdrawal assay, finding no significant difference across the agonists. Additionally, this finding was supported by Fang et al.'~, who studied the naloxone pA: against these 3 agonists at supraspinal sites in the rat. The determination of naloxone affinity in vivo, however, involves methodology which includes highly questionable assumptions regarding administered dose and measurement at times of equilibrium. The determined value in vivo may be associated with a lack of precision which makes it impossible to distinguish between affinity at /~-and b-sites. Thus, conclusions made on the basis of differential antagonism appear to offer much stronger evidence. Further, other approaches such as the study of Mathiasen and Vaught 2~, who determined the potency of/~-and 6-agonists in/~-deficient strains of mice, strongly support the present conclusion of supraspinal b-mediated antinociception in this species. Additionally, Jensen and Yaksh e2 found that b-, but not/~-agonists produce thermal antinociception when given into the medullary reticular formation of the rat by direct microinjection, further supporting the conclusions of the present study of b-receptor involvement in this endpoint.
The effects of fl-FNA on morphine and DPDPE antinociception were also examined at the spinal level. While high doses of fl-FNA antagonized both morphine and DPDPE, lower doses (0.01 and 0.005 ktg) selectively blocked i.th. morphine but not i.th. DPDPE antinociception. This is in agreement with previous findings 19 showing that i.th. fl-FNA (0.5/~g at -2 h) pretreatment blocked the inhibition of substance P-induced behaviors (hind-limb scratching) by i.th. morphine, but not i.th. DADLE. It has been previously shown that DADLE has both/~-and b-activity u'3°, a view supported by the fact that the dose of fl-FNA (0.5/~g), used in previous work 19, was selective against the/~-effects of DADLE.
Earlier studies have provided evidence for spinal b-involvement in thermal antinociception. Tung and Yaksh 37 have reported that in rats made tolerant to morphine by repeated systemic morphine administration, no significant change occurred in the doseresponse curve of i.th. DADLE in the hot-plate test. In a similar study, Tseng 36 reported that in morphinetolerant rats, only a partial cross-tolerance developed to the antinociceptive effects of i.th. DADLE in the tail-flick test after chronic spinal morphine infusion. Important recent evidence for the supraspinal involvement of the d-receptor has also been demonstrated. While microinjections of u-and d-agonists into the periaqueductal gray of the rat produced maximal elevation in the tail-flick test, only b-agonists produced antinociception when injected into the medial/paramedial medullary reticular formation 2:. These findings strongly suggest that d-selective agonists produce their antinociception by action at the b-, rather than the/~-receptor, and are in agreement with the present findings.
In summary, the present study set out to determine the role of the d-receptor, if any, at both supraspinal and spinal sites in the mediation of antinociception in mice using a test where heat was the nociceptive stimulus. The approach taken was to use highly selective agonists and antagonists in an attempt to demonstrate differential antagonism of the antinociceptive effects of the selective agonists in the brain and spinal cord. By blocking the supraspinal and spinal antinociceptive effects of DPDPE, but not DAGO or morphine, with the d-selective antagonist ICI 174,864, strong evidence has been provided for the involvement of cerebral and spinal b-opioid receptors in antinociception. The kt-selective antagonist, fl-FNA, provided additional and supporting evidence for this conclusion. Owing to the t~-selectivity of the agonist DAGO as well as the antagonist, fl-FNA, and the bselectivity of the agonist DPDPE and the antagonist ICI 174,864, we now suggest that the b-opioid receptor plays an intimate and separate role from that of the/z-receptor in the supraspinal and spinal mediation of thermal antinociception in the mouse.
